Adagio Medical Holdings, Inc. (ADGM)
NASDAQ: ADGM · Real-Time Price · USD
0.9702
+0.0163 (1.71%)
At close: Jan 9, 2026, 4:00 PM EST
0.9103
-0.0599 (-6.17%)
After-hours: Jan 9, 2026, 6:11 PM EST
Company Description
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.
It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia.
The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories.
Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Adagio Medical Holdings, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Todd Usen |
Contact Details
Address: 26051 Merit Circle, Suite 102 Laguna Hills, California 92653 United States | |
| Phone | 949 348 1188 |
| Website | adagiomedical.com |
Stock Details
| Ticker Symbol | ADGM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2006986 |
| CUSIP Number | 00534B100 |
| ISIN Number | US00534B1008 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Todd Usen | Chief Executive Officer and Director |
| Deborah Kaster | Chief Financial Officer and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2025 | 424B3 | Prospectus |
| Dec 16, 2025 | 424B3 | Prospectus |
| Dec 16, 2025 | 8-K | Current Report |
| Dec 12, 2025 | EFFECT | Notice of Effectiveness |
| Dec 12, 2025 | 424B3 | Prospectus |
| Dec 12, 2025 | 424B3 | Prospectus |
| Dec 12, 2025 | 424B3 | Prospectus |
| Dec 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 11, 2025 | 8-K | Current Report |
| Nov 24, 2025 | S-3 | Registration statement under Securities Act of 1933 |